FDA announces recall of hypertension medications due to potential cancer risk

WTH?

Read the full article here

Categories: Cardiologists, Cardiology News and Journals, Latest Headlines

Tweets with this article

Joel Kahn

WTH?

Related Articles

Regressing calcifications in the carotid artery: What’s going on? A case series

Read the full article here

john doe 5 July 5, 2025

Coronary Artery Calcium and cardiovascular risk factors analysis after Radiotherapy for breast cancer

Read the full article here

john doe 5 July 5, 2025

Recent Nutraceutical Interventions for Hypertension: A Comprehensive Review of Randomized Clinical Evidence

Read the full article here

john doe 5 July 5, 2025

The Implications of Alpha-Gal Syndrome for Dental and Medical Treatment

Read the full article here

john doe 5 July 4, 2025

150 minutes of exercise per week could help reverse prediabetes

Read the full article here

john doe 5 July 4, 2025

Factors influencing health-promoting lifestyles in patients after percutaneous coronary intervention: A cross-sectional study

Read the full article here

john doe 5 July 4, 2025

Poor lifestyle habits nearly double your chance of developing AFib

Read the full article here

john doe 5 July 4, 2025

Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer

Read the full article here

john doe 5 July 3, 2025

Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)

Read the full article here

john doe 5 July 3, 2025

Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study

Read the full article here

john doe 5 July 3, 2025